(Q33363618)

English

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

David C Smith

4

0 references

author name string

Tahir Latif

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Laura Wood

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cindy Connell

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David Vaughn

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David Lebwohl

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David Peereboom

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

79-84

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1023/b:drug.0000047109.76766.84

0 references

Phase II trials with cis-dichlorodiammineplatinum(II) in the treatment of urothelial cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of JM-216 in cervical cancer: an NCIC CTG study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oestrogen Therapy and Serum Cortisol in Carcinoma of the Prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2003.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platinum agents and secondary myeloid leukaemia: two cases treated only with platinum-based drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical antitumor activity of orally administered platinum (IV) complexes

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carboplatin in advanced hormone refractory prostatic cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of leukemia after platinum-based chemotherapy for ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New therapeutic strategies for prostate cancer: reasons for optimism and reflection.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of previously untreated (by hormonal manipulation) stage D adenocarcinoma of prostate with combined orchiectomy, estrogen, and cis diamminedichloroplatinum

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT).

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematologic consequences of exposure to ionizing radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15528984

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/B:DRUG.0000047109.76766.84

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33363618&oldid=1856149141"